# BioSkepsis vs ChatGPT for Research — When a Specialist Beats a Generalist > **Reviewed:** 2026-04-22 > **Canonical HTML:** https://bioskepsis.ai/blog/bioskepsis-vs-chatgpt-for-research > **Publisher:** BioSkepsis (EFEVRE TECH LTD, Larnaca, Cyprus) ## TL;DR ChatGPT is a phenomenal general-purpose assistant. For drafting, brainstorming, rephrasing, and writing code it is, frankly, excellent — and a lot of what gets criticised as "lazy use of ChatGPT for research" is actually legitimate work that ChatGPT does well. Where ChatGPT struggles is in answering biomedical research questions with verifiable citations: the well-documented issue is **citation hallucination** — plausible-looking references that do not exist. BioSkepsis is a biomedical AI research assistant built specifically to solve that problem. Retrieval runs on a biology-native knowledge graph (Gene Ontology + MeSH + genes) across 40M+ curated biomedical papers; every claim is grounded in a real, retrievable source; the system declines when evidence is insufficient rather than inventing one. This is not a "ChatGPT is bad" page. It is a page about when to pick a specialist over a generalist. ## What ChatGPT actually is (and what it's great at) ChatGPT is a general-purpose large language model from OpenAI, trained on a massive web corpus. Depending on the plan and tools enabled, it can also browse the web, execute code, analyse files and images, and call external tools. For research workflows, ChatGPT is legitimately excellent at: - **Drafting and rephrasing** — first drafts of abstracts, cover letters, grant summaries, lay summaries. - **Brainstorming** — ideation, outlining, "what angles am I missing?" exploration. - **Code and data tasks** — R/Python scripts for basic stats, plotting, data cleaning. - **Quick explanations** — "explain this acronym", "walk me through this equation". - **Language polish** — non-native English speakers use ChatGPT legitimately to improve manuscript clarity. - **Translation and summarisation** of text you already have. Where it struggles is the specific claim that matters most for research: *"here is a fact, and here is the paper it came from."* ## The citation hallucination problem This is documented in both academic and library literature. A few illustrative findings: - Studies testing ChatGPT on medical reference generation have repeatedly found that a substantial fraction of generated citations are non-existent: the authors, journal and year often look plausible, but the paper is fabricated or the DOI does not resolve. - Even when ChatGPT uses browsing to retrieve real URLs, it can misattribute claims to the wrong paper or to sections of a paper that do not support the claim. - Hallucination rates vary with prompt, model version, and whether browsing or a RAG layer is enabled — but the failure mode does not disappear. This is a structural feature of how general LLMs generate text: they model *what a plausible citation looks like*, not *what the literature actually contains*. When you are not building a corpus-grounded answer, you are building a plausible-sounding one. For grant writing, manuscripts, regulatory filings and anything that a reviewer will check: that is not acceptable. ## What BioSkepsis does differently BioSkepsis is built specifically to make the "here is a fact, and here is the paper" workflow trustworthy for biomedical research: - **Retrieval-first architecture.** Every answer starts from retrieved real papers. The model does not invent a citation because it cannot — there is no free-text citation generation step. - **Biology-native knowledge graph.** Retrieval is weighted by Gene Ontology terms, MeSH descriptors, gene symbols, and pathway relationships. Queries about biomedical concepts return biologically relevant papers, not just text-similar ones. - **Full-text reasoning.** Answers are grounded in methods, controls, and supplementary material — not only abstracts. - **Curated biomedical corpus.** 40M+ peer-reviewed biomedical papers. - **Explicit declines.** When evidence is insufficient, BioSkepsis says so. It does not confabulate a plausible answer to be helpful. - **Lab-result interpretation.** Users can upload experimental notes and have them mapped against published evidence. ## Feature comparison | Feature | BioSkepsis | ChatGPT (for research) | | --- | --- | --- | | Primary job-to-be-done | Cited biomedical answers grounded in literature | Generalist assistant — drafting, code, brainstorming, chat | | Domain focus | Biomedical & life-science native | General-purpose, all topics | | Paper corpus | 40M+ curated biomedical papers | None natively; may browse the web on higher plans | | Retrieval model | Biology-native knowledge graph (GO + MeSH + genes) | LLM pretraining + optional browsing | | Citation grounding | Every claim tied to a retrieved real source | Citations often plausible-looking but unreliable; browsing mitigates but does not eliminate | | Full-text reasoning | Yes — methods, controls, supplementary | Only if you upload a specific PDF | | Hallucination handling | Declines when evidence is insufficient | Will produce a plausible answer regardless | | Lab-result interpretation | Upload notes → mapped against literature | You can paste notes, but no literature grounding | | Free tier | Yes — ongoing, 100 papers/session | Yes (limited model access) | | Zotero / reference-manager sync | Yes | No native integration | ## Free tier availability Both tools have free access. We do not print dollar amounts here; verify pricing on each vendor page. - **BioSkepsis — free tier: yes.** Basic tier includes semantic search, landscape graph, and hypothesis/methodology generation, capped at 100 papers per session. Ongoing, no time limit, no credit card. - **ChatGPT — free tier: yes.** Access to a default model with limited usage on advanced features; paid plans unlock more capable models, higher usage and additional tools. ## Worked example: "What is the evidence that semaglutide reduces MACE in non-diabetic patients with obesity?" Same question, two tools. (Illustrative; exact outputs vary by model version, plan, browsing status and prompt.) ### ChatGPT response (typical failure mode) > Semaglutide has shown cardiovascular benefits in non-diabetic patients with obesity. The SELECT trial (2023, published in NEJM) reported a 20% reduction in major adverse cardiovascular events (MACE) over a 3.3-year follow-up in patients with BMI ≥ 27 and established cardiovascular disease but without diabetes. See Lincoff AM et al., NEJM 2023;389:2221–2232. > > Additional supporting evidence includes a 2022 meta-analysis in *Lancet Diabetes & Endocrinology* by Smith J et al., which pooled 8 semaglutide trials and reported consistent cardiovascular benefit. Looks great — except the second reference is the one to check. The Lincoff/SELECT citation is real and accurately described. The *Smith J et al. Lancet Diabetes & Endocrinology* meta-analysis *may or may not* exist — LLMs are known to invent co-authors, journal names, and years that look correct. Without browsing, ChatGPT cannot tell you; with browsing enabled, it may retrieve a genuine but different paper and summarise it as if it were the one it just named. Either way, a researcher quoting this in a grant must manually verify every citation. ### BioSkepsis response (how grounding works) > **Short answer.** In non-diabetic patients with established cardiovascular disease and obesity (BMI ≥ 27), semaglutide 2.4 mg weekly reduced the primary composite MACE endpoint by approximately 20% over a median follow-up of ~3.3 years (SELECT trial) [1]. > > **Trial details (from full text).** N = 17,604; double-blind, placebo-controlled; primary endpoint was a composite of cardiovascular death, non-fatal MI, and non-fatal stroke. Benefit was consistent across prespecified subgroups of age, sex, and baseline BMI [1]. > > **Mechanistic context (knowledge graph).** GLP-1 receptor agonism → weight reduction, improved glycaemic indices, reduced systemic inflammation. Cardiovascular benefit is not fully explained by weight loss alone — mediation analyses in SELECT suggest direct vascular effects [1, 2]. > > **Evidence strength:** strong for MACE reduction in the studied population (single large RCT, pre-specified endpoint). Generalisability to lower-BMI or non-CVD populations is not established. > > *Citations: [1] Lincoff et al., NEJM 2023; [2] SELECT mediation sub-analysis, peer-reviewed publication.* Every reference resolves. Where a cited sub-analysis does not exist, BioSkepsis omits it rather than inventing one. Every factual claim ties to a retrieved passage from full text. ### What this means in practice - If you are drafting a cover letter, brainstorming study designs, or writing a Python snippet, ChatGPT is a fine tool. - If you are writing a grant, a manuscript, a regulatory document, or anything where a reviewer is going to check citations, using BioSkepsis (or another grounded tool) for the citation-bearing paragraphs is not optional. Pasting ChatGPT's bibliography into a submitted paper is how retractions start. ## When to choose which ### Choose BioSkepsis for any claim that will be cited If you are going to attribute a statement to a paper, the citation must be real and the paper must actually support the claim. BioSkepsis guarantees the first by construction and makes the second verifiable by grounding in retrieved full text. ChatGPT does neither natively. ### Choose ChatGPT for drafting, rephrasing, and language work For turning bullet points into prose, summarising text you already have, improving flow, or translating: ChatGPT is excellent. Pair it with BioSkepsis for the citation layer and you have a complete workflow. ### Choose BioSkepsis for biomedical-specific reasoning BioSkepsis knows biology natively — Gene Ontology terms, MeSH descriptors, gene symbols, pathways. ChatGPT will pattern-match biomedical vocabulary but without a biology-native retrieval layer. For mechanistic questions, specialist reasoning is materially better. ### Choose ChatGPT for general productivity Email drafts, meeting notes, code snippets, one-off explanations — ChatGPT is the right default. We use it daily. It just is not the right tool for cited research claims. ### Choose BioSkepsis if you want to upload lab results BioSkepsis accepts user-uploaded experimental notes and maps them against the literature. ChatGPT can read files, but it has no curated biomedical corpus to ground them against. ## Use them together A sensible division of labour: 1. **Brainstorm and outline with ChatGPT.** "What angles should I cover in a review on GLP-1 and cardiovascular outcomes?" 2. **Research and cite with BioSkepsis.** For each claim, retrieve the actual supporting paper(s) and quote from full text. 3. **Polish with ChatGPT.** Tighten prose, improve flow, adapt register for your audience. 4. **Verify manually.** Always click through citations before submission, regardless of tool. The two tools are not competitors in practice. ChatGPT is a general-purpose assistant; BioSkepsis is the cited-research layer. Using both well is probably the right answer. ## FAQ ### Can I just use ChatGPT for research? For drafting, brainstorming, rephrasing, and coding — yes, it is a fine tool. For anything that requires verifiable citations — grants, manuscripts, systematic reviews, regulatory documents — ChatGPT alone is risky because of documented citation hallucination. A specialist like BioSkepsis is the right tool for the citation-bearing work; ChatGPT can handle the surrounding prose. ### Does ChatGPT hallucinate citations? Yes, this is well-documented in both academic studies and library guidance. ChatGPT can generate plausible-looking references (authors, journal, year, DOI) for papers that do not exist, or misattribute real claims to the wrong paper. Browsing-enabled plans reduce the rate but do not eliminate the failure mode. ### How does BioSkepsis avoid citation hallucination? BioSkepsis is retrieval-first. Every answer is built from real papers retrieved from a 40M+ biomedical corpus. There is no free-text citation generation step, so there is no plausible-but-fake reference. When evidence is insufficient, BioSkepsis declines rather than inventing a plausible answer. ### Is ChatGPT biomedical-specific? No. ChatGPT is a generalist model trained on broad web text. It knows biomedical vocabulary because biomedical content appears in the training data, but it has no biomedical-specific retrieval layer, no Gene Ontology / MeSH weighting, and no curated biomedical corpus to ground answers against. BioSkepsis is purpose-built for life-science research. ### Can ChatGPT read PDFs of papers? On paid plans, yes — ChatGPT can read uploaded PDFs and answer questions about them. That is genuinely useful for reading a single paper you already have. It is not a substitute for corpus-level retrieval across 40M+ biomedical papers when your question is "what does the literature say about X?" ### Can I use BioSkepsis for non-biomedical questions? BioSkepsis is tuned for biology, medicine, pharma, biotech, and agricultural/veterinary/environmental science. For questions outside those areas — economics, sociology, computer science — a general tool (including ChatGPT for non-cited work, or Semantic Scholar / Elicit for cited work) will be a better fit. ### Are hallucination rates actually measurable? Yes — there are published studies measuring citation accuracy of ChatGPT on medical and scientific queries. Reported rates of fabricated or misattributed references vary by model version and setup but are consistently non-trivial. Check the HKUST Library review and similar literature for current benchmarks. ## Sources 1. OpenAI: ChatGPT documentation 2. Published studies on LLM citation accuracy in medical and scientific domains 3. [HKUST Library: Trust in AI evaluation](https://library.hkust.edu.hk/sc/trust-ai-lit-rev/) 4. Academic library guidance on responsible use of generative AI for research ## Legal notice "ChatGPT" and "OpenAI" are trademarks of OpenAI, Inc. and are used here for identification and comparison only under the doctrine of nominative fair use. BioSkepsis is not affiliated with, endorsed by, or sponsored by OpenAI, Inc. All product claims above are sourced from public documentation, peer-reviewed studies, and third-party reviews, verified on 2026-04-22. Features and capabilities of either product may have changed since; always verify on the vendor's live page.